How should Trelegy (fluticasone furoate, vilanterol, umeclidinium) be prescribed, and what are its contraindications, required patient counseling, and monitoring recommendations?

Trelegy Prescribing and Management

Trelegy (fluticasone furoate/umeclidinium/vilanterol) should be prescribed as once-daily single-inhaler triple therapy at 100/62.5/25 mcg for COPD patients inadequately controlled on dual therapy (LABA/LAMA or ICS/LABA), with absolute contraindications being severe milk protein hypersensitivity and use in acute exacerbations or status asthmaticus. 1

Contraindications

Trelegy is absolutely contraindicated in:

• Primary treatment of status asthmaticus or acute COPD episodes requiring intensive measures 1
• Severe hypersensitivity to milk proteins (contains lactose monohydrate with milk proteins) 1
• Demonstrated hypersensitivity to fluticasone furoate, umeclidinium, vilanterol, or any excipients 1

Prescribing Indications

Prescribe Trelegy for:

• Moderate-to-severe COPD patients symptomatic despite ≥3 months of dual therapy (LABA/LAMA or ICS/LABA) 2, 3
• Patients with history of exacerbations on dual therapy 2
• The 2023 Canadian Thoracic Society guideline supports triple therapy escalation in patients with persistent symptoms or exacerbations 2

Real-world data from France demonstrates 92% of patients received prior dual or triple therapy before Trelegy initiation, confirming appropriate use patterns 4.

Dosing

• Standard dose: 100/62.5/25 mcg once daily via ELLIPTA inhaler 1, 3
• Higher dose available: 200/62.5/25 mcg for asthma patients requiring higher ICS doses 5
• Administer once daily at the same time each day 1

Critical Patient Counseling Points

Device Technique

• Opening the cover prepares ONE dose - the counter decreases by 1 1
• Do not open cover until ready to inhale - opening and closing without inhaling wastes the dose 1
• Do not shake the inhaler 1
• Breathe out fully away from mouthpiece, then take one long, steady, deep breath through mouth 1
• Hold breath 3-4 seconds after inhalation 1
• Rinse mouth with water without swallowing after each use to prevent oral thrush 1

Storage and Disposal

• Write "Tray opened" and "Discard" dates on label when first opening 1
• Discard 6 weeks after opening tray OR when counter reads "0", whichever comes first 1
• Store at room temperature (68-77°F) in dry place away from heat and sunlight 1
• Keep in unopened tray until ready for use 1

Warning Signs Requiring Immediate Action

Stop Trelegy and call provider immediately if:

• Acute narrow-angle glaucoma symptoms: eye pain/discomfort, nausea/vomiting, blurred vision, seeing halos around lights, red eyes 1
• Urinary retention symptoms: difficulty urinating, painful urination, frequent urination in weak stream 1

Call provider for:

• Paradoxical bronchospasm (worsening breathing immediately after use) 1
• Signs of pneumonia (increased sputum, fever, chest pain) 1
• Cardiovascular symptoms (chest pain, rapid heart rate, palpitations) 1

Monitoring Recommendations

Baseline Assessment

• Pulmonary function testing (FEV1) 3
• Exacerbation history in past 12 months 2
• Current symptom burden (CAT score or similar) 6
• Ophthalmologic examination if risk factors for glaucoma or cataracts 1
• Blood glucose if diabetic 1
• Bone density if osteoporosis risk factors 1

Ongoing Monitoring

• Regular eye exams while on therapy to monitor for glaucoma, cataracts, and vision changes 1
• Blood glucose monitoring - can cause hyperglycemia 1
• Serum potassium - can cause hypokalemia 1
• Exacerbation frequency - real-world data shows reduction from 1.4 to 0.2 events/year 6
• Symptom assessment (CAT scores improved by mean 2.6 units at 12 months) 6
• Growth monitoring in children - can cause slowed growth 1
• Cardiovascular monitoring in patients with CV disease - Japanese surveillance showed low CV event incidence (palpitations in 2/286 patients) 5

Common Adverse Effects to Counsel On

Most common (COPD patients): 1

• Upper respiratory tract infection
• Pneumonia (monitor closely)
• Bronchitis
• Oral/pharyngeal thrush (prevented by mouth rinsing)
• Headache, back pain, joint pain
• Dysphonia (hoarseness)
• Urinary tract infection symptoms
• Taste disturbance

Serious but less common: 1

• Bone thinning/osteoporosis
• Tremor and nervousness
• Urinary retention (1 serious case in 286 patients in Japanese surveillance) 5

Clinical Effectiveness Evidence

Real-world effectiveness data demonstrates:

• Significant FEV1 improvement of 93-95 mL versus comparators 6, 3
• Clinically meaningful CAT score reduction of 2.6 units at 12 months 6
• 78-88% reduction in exacerbation rates in real-world practice 6, 7, 8
• 12% lower exacerbation rate versus budesonide/glycopyrrolate/formoterol in US Medicare population 8
• 11% lower all-cause mortality risk versus budesonide/glycopyrrolate/formoterol at 12 months 8

Key Pitfalls to Avoid

• Do not prescribe for acute symptom relief - this is maintenance therapy only 1
• Do not use as rescue medication - patients need separate short-acting bronchodilator 1
• Do not prescribe to patients with milk protein allergy - contains lactose with milk proteins 1
• Do not assume patients understand device technique - demonstrate and verify proper use 1
• Do not forget mouth rinsing counseling - critical for preventing oral candidiasis 1
• Do not overlook the 6-week discard date - medication degrades after tray opening 1